These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34629881)

  • 1.
    Yu R; Sun T; Zhang X; Li Z; Xu Y; Liu K; Shi Y; Wu X; Shao Y; Kong L
    Onco Targets Ther; 2021; 14():4967-4978. PubMed ID: 34629881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.
    Fitzpatrick MJ; Boiocchi L; Fathi AT; Brunner AM; Hasserjian RP; Nardi V
    Histopathology; 2022 Oct; 81(4):496-510. PubMed ID: 35869818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
    Oliva EN; Latagliata R; Sabattini E; Mammì C; Cuzzola M; D'Errigo MG; Cannatà MC; Bova I; Capodanno I; Palumbo GA; Pane F; Reda G; Fianchi L; Riva M; Poloni A
    Am J Blood Res; 2021; 11(4):417-426. PubMed ID: 34540351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis.
    Brunetti B; de Biase D; Dellapina G; Muscatello LV; Ingravalle F; Tura G; Bacci B
    Animals (Basel); 2023 Mar; 13(5):. PubMed ID: 36899756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized p53 immunohistochemistry is an accurate predictor of
    Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
    J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
    [No Abstract]   [Full Text] [Related]  

  • 7. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
    Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
    Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutations determined by targeted NGS in breast cancer: a case-control study.
    Andrikopoulou A; Terpos E; Chatzinikolaou S; Apostolidou K; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA; Zagouri F
    Oncotarget; 2021 Oct; 12(21):2206-2214. PubMed ID: 34676052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
    Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
    J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemistry as an accurate tool for the assessment of
    Rusu S; Verocq C; Trepant AL; Maris C; De Nève N; Blanchard O; Van Campenhout C; De Clercq S; Rorive S; Cotoi OS; Decaestecker C; Salmon I; D'Haene N
    Mol Clin Oncol; 2021 Dec; 15(6):270. PubMed ID: 34790354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing.
    Ge S; Li B; Li Y; Li Z; Liu Z; Chen Z; Wu J; Gao J; Shen L
    Am J Cancer Res; 2017; 7(7):1540-1553. PubMed ID: 28744403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
    Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
    Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
    Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
    J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic Mutation Profiles Revealed by Next Generation Sequencing (NGS) in 39 Chinese Hepatocellular Carcinoma Patients.
    Ke L; Shen J; Feng J; Chen J; Shen S; Li S; Kuang M; Liang L; Lu C; Li D; He Q; Peng B; Hua Y
    Front Mol Biosci; 2021; 8():800679. PubMed ID: 35118119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.